QbD Based Media Development for the Production of Fab Fragments in <i>E. coli</i>
Ranibizumab is a biotherapeutic Fab fragment used for the treatment of age-related macular degeneration and macular oedema. It is currently expressed in the gram-negative bacterium, <i>Escherichia coli</i>. However, low expression levels result in a high manufacturing cost. The protein e...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-03-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/6/2/29 |